Skip to content
RDL Network logo
Su1751: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY TUMOR RESPONSE MEASURES FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) — Lorenza Rimassa (2025) | RDL Network